A5080092427- Hepatitis B Virus Studies
- Hepatitis C virus research
- Liver Disease Diagnosis and Treatment
- Hepatitis Viruses Studies and Epidemiology
- Viral gastroenteritis research and epidemiology
- Animal Virus Infections Studies
- Monoclonal and Polyclonal Antibodies Research
- HIV Research and Treatment
- Bacteriophages and microbial interactions
- Reproductive tract infections research
- Viral Infections and Immunology Research
- Protein purification and stability
- Animal Disease Management and Epidemiology
- Diabetes and associated disorders
- vaccines and immunoinformatics approaches
- Long-Term Effects of COVID-19
- Immunotherapy and Immune Responses
- Cervical Cancer and HPV Research
- HIV/AIDS drug development and treatment
- Hemoglobinopathies and Related Disorders
- COVID-19 Clinical Research Studies
- Biochemical and Molecular Research
- Herpesvirus Infections and Treatments
- Liver Diseases and Immunity
- Systemic Lupus Erythematosus Research
University of Nicosia
2013-2023
Royal Victoria Hospital
2023
University of Ulster
2023
Nicosia General Hospital
2021
Imperial College London
2005-2020
St Mary's Hospital
1997-2015
National and Kapodistrian University of Athens
1981-2014
Council of Science Editors
2014
Baqiyatallah University of Medical Sciences
2013
St George's, University of London
2013
An RNA virus, designated hepatitis G virus (HGV), was identified from the plasma of a patient with chronic hepatitis. Extension an immunoreactive complementary DNA clone yielded entire genome (9392 nucleotides) encoding polyprotein 2873 amino acids. The is closely related to GB C (GBV-C) and distantly GBV-A, GBV-B. HGV associated acute Persistent viremia detected for up 9 years in patients transfusion-transmissible. It has global distribution present within volunteer blood donor population...
Hepatitis B virus DNA (HBV DNA) in serum was measured by a Spot hybridization technique consecutive series of 79 cases with chronic HBV infection from Taiwan. found 96.3% (52/54) HBeAg-positive, 66% (2/3) neither HBeAg or anti-HBe and 63.6% (14/22) positive patients. The levels the HBe-Ag-positive patients were significantly higher than (median, 944 vs. 58 pg per ml, p less 0.001). mean ages increased 28.7 years for high DNA, to 34.7 those low (p 0.01) 41.0 without 0.05 when compared level...
Twenty–one pretreatment variables were assessed for their significance in response prediction using data from 114 patients given α–interferon chronic hepatitis B virus infection. In those who had received a minimum of 90 million units per m 2 total dose over 12 weeks, negative anti–human immunodeficiency antibody status (p < 0.001), active on liver biopsy 0.005), high AST level low DNA 0.001) and history acute 0.005) all associated with an increased likelihood univariate analysis. On...
Reports of cerebral dysfunction in chronic hepatitis C virus (HCV) infection have led to the suggestion that HCV may infect central nervous system (CNS). We used reverse transcription-PCR, cloning, and sequencing define quasispecies for internal ribosomal entry site (IRES) hypervariable region 1 (HVR1) autopsy-derived brain, liver, lymph node, serum samples. There was evidence tissue compartmentalization sequences brain two patients, with between 24 55% brain-derived IRES absent from serum,...
An epidemic of acute hepatitis C virus (HCV) infection among HIV-positive men who have sex with is occurring in urban centers Western Europe and the United States. Early diagnosis treatment HCV results improved sustained virological response rates. This study compared sensitivity reverse transcriptase PCR (RT-PCR) versus antibody screening for early patients estimated length time from to development anti-HCV antibodies.Patients St Mary's Acute Hepatitis Cohort (SMACC) were recruited...
<h3>Objective</h3> An epidemic of acute hepatitis C virus (HCV) infection in HIV-positive men-who-have-sex-with-men (MSM) is emerging Europe, Australia and the USA. The aim this study was to characterise natural history primary HCV setting assess host viral factors which predict spontaneous clearance. <h3>Methods</h3> This prospective longitudinal cohort carried out 112 patients who were followed a single centre (the St Mary9s Acute Cohort). Plasma peripheral blood mononuclear cells (PBMCs)...
S ummary After a first exposure to factor VIII concentrates, 9/9 British patients treated with U.S.A.‐derived commercial products, and 10/12 volunteer (NHS) developed acute non‐A, non‐B (NANB) hepatitis. Hepatitis following products was more severe, of shorter incubation. High previous NHS blood seemed prevent but not VIII‐induced hepatitis; the latter also attenuated by administration immune serum globulin (ISG). IX concentrates without ISG, 4/4 short incubation NANB one contracted...
Previous studies have suggested that hepatitis B virus (HBV) variants may account for the presence of HBV DNA in surface antigen (HBsAg)-negative patients (occult infection). However, it is not known how widespread these are and they influence course liver disease. To determine prevalence within major hydrophilic region (MHR) HBsAg, we investigated 2,565 subjects, including subjects with chronic hepatitis, cryptogenic cirrhosis, hemodialysis patients, blood donors. Fifty-one them had occult...
In a randomized controlled trial, 41 chronic hepatitis B virus carriers were allocated, by opening numbered computerized randomization envelopes, to receive recombinant interferon-α2A at three different doses: 2.5; 5.0, and 10.0 mU per m 2 . Thirty-two patients received treatment (6 for 3 months, 26 6 months), 9 controls (received no treatment). Ninety-three cent of our homosexual, 41% had anti-HTLV-III in their serum None the control lost HBeAg. contrast, six anti-HTLV-III-negative (33%)...
SUMMARY. This is the first double‐blind controlled study of famciclovir, an oral antiviral agent, as potential therapy for chronic hepatitis B virus (HBV) carriers. A fall more than 90% in HBV DNA levels was noted six 11 evaluable patients treated with a 10 day course famciclovir. Further studies prolonged are ongoing.
The relationship between the histological diagnosis and serological tissue markers of HBV replication in 41 Greek 29 British patients with chronic infection were studied. All nine 13 who HBeAg positive had HBV-DNA serum HBcAg expression hepatocytes. majority (73%) these active liver disease. Forty seven per cent 19% anti-HBe continued to display or without detected serum. but three persistently Continuing inflammatory activity liver, however, was also found 31% no evidence replication. In...
There are two hypotheses explaining a fulminant outcome after hepatitis B virus (HBV) infection, both of which may be applicable at the same time: (i) basal core promoter (BCP) mutations increase viral replication, allowing rapid spread through liver, and (ii) pre-core (pre-C) abrogating e antigen (HBeAg) synthesis remove its tolerogenic effect, leading to vigorous immune response. This study investigated effect these on replication efficiency HBeAg production. Substitutions A1762T/G1764A...
Antibody to the common “a” determinant of hepatitis B surface antigen (HBsAg) protects against infection with virus. A number variant antigens amino acid substitutions within have been described in patients around world. Both wild type and HBsAgs were expressed yeast Pichia pastoris semi-purified quantitated. The effect on antigenicity these changes was investigated a quantitative fashion using four monoclonal antibodies known bind different epitopes determinant. results suggest that...
SUMMARY. We tested the sera of 67 consecutive patients for hepatitis G virus (HGV) RNA by reverse transcriptase‐polymerase chain reaction (RT‐PCR). These (42 males and 2 5 females, median age 35 years, range 13–64 years) had liver disease unknown aetiology were without markers (A‐E) viruses or signs genetically determined, autoimmune, alcoholic drug‐induced disease. The controls in this study 110 (50 females 60 males, 45 9–65 with chronic B (HBV) infection (19 patients) C (HCV) (91...
In a randomised controlled trial recombinant interferon alpha 2A (Roferon-A, rIFN alfa A) given at dosage of 10 million units (MU)/m2 thrice weekly for six months was significantly better (p less than 0.02) no treatment in producing sustained loss hepatitis Be antigen (HBeAg) B virus (HBV) chronic carriers. Although lower doses (5 MU/m2 and 2.5 MU/m2) also produced some responses, the seroconversion rate not greater that observed control group. Sixteen 45 patients receiving were human...
The presence of unique hepatitis B virus (HBV) variants has been investigated in two Chinese patients with chronic liver disease, whose sera were positive for HBV-DNA by dot blot hybridization or polymerase chain reaction (PCR) but surface antigen (HBsAg)-negative conventional polyclonal antibody based immunoassays. PCR amplification followed direct sequencing showed an insertion six nucleotides, which introduced additional amino acids between codons 122 and 123 one patient (Isolate 1),...